About: A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Avastin and Roferon in Renal Cell Carcinoma (AVOREN) demonstrated efficacy for bevacizumab plus interferon-alpha 2a (INF; 9 MIU tiw) in first-line metastatic renal cell carcinoma (mRCC). We evaluated bevacizumab with low-dose IFN mRCC to determine whether clinical benefit could be maintained with reduced toxicity.
  • Avastin and Roferon in Renal Cell Carcinoma (AVOREN) demonstrated efficacy for bevacizumab plus interferon-alpha 2a (INF; 9 MIU tiw) in first-line metastatic renal cell carcinoma (mRCC). We evaluated bevacizumab with low-dose IFN mRCC to determine whether clinical benefit could be maintained with reduced toxicity. (en)
Title
  • A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN
  • A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN (en)
skos:prefLabel
  • A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN
  • A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN (en)
skos:notation
  • RIV/61989592:15110/13:33144214!RIV14-MSM-15110___
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • S
http://linked.open...iv/cisloPeriodika
  • 9
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 58774
http://linked.open...ai/riv/idVysledku
  • RIV/61989592:15110/13:33144214
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • VEGF; interferon; immunotherapy; bevacizumab; angiogenesis; renal cell carcinoma (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV
  • [7AC871651291]
http://linked.open...i/riv/nazevZdroje
  • Annals of Oncology
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 24
http://linked.open...iv/tvurceVysledku
  • Melichar, Bohuslav
  • Bellmunt, J.
  • Ivanov, S.
  • Alekseev, B.
  • Bracarda, S.
  • Fernebro, E.
  • Gore, M.
  • Janciauskiene, R.
  • Jethwa, S.
  • Magne, N.
  • Matveev, V.
  • Mickisch, G.
  • Moorselaar, R.
  • Mulders, P.
  • Osborne, S.
  • Staehler, M.
  • Zyryanov, A.
issn
  • 0923-7534
number of pages
http://bibframe.org/vocab/doi
  • 10.1093/annonc/mdt228
http://localhost/t...ganizacniJednotka
  • 15110
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 110 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software